3,264 Shares in Johnson & Johnson (NYSE:JNJ) Bought by Sovereign Investment Advisors LLC

Sovereign Investment Advisors LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 3,264 shares of the company’s stock, valued at approximately $472,000.

A number of other hedge funds have also bought and sold shares of the business. Gitterman Wealth Management LLC lifted its holdings in Johnson & Johnson by 10.3% during the fourth quarter. Gitterman Wealth Management LLC now owns 16,596 shares of the company’s stock worth $2,400,000 after acquiring an additional 1,553 shares during the period. Greenwich Wealth Management LLC lifted its holdings in Johnson & Johnson by 29.1% during the fourth quarter. Greenwich Wealth Management LLC now owns 4,143 shares of the company’s stock worth $599,000 after acquiring an additional 934 shares during the period. Ascent Capital Management LLC bought a new stake in Johnson & Johnson during the fourth quarter worth $215,000. Pollock Investment Advisors LLC bought a new stake in Johnson & Johnson during the fourth quarter worth $1,040,000. Finally, one8zero8 LLC bought a new stake in Johnson & Johnson during the fourth quarter worth $9,930,000. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Raymond James lowered their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research note on Monday, March 10th. Leerink Partners lowered their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, Barclays boosted their target price on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 28th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $162.94 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The business has a 50-day simple moving average of $154.98 and a 200 day simple moving average of $156.32. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock has a market cap of $392.29 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the previous year, the company posted $2.29 earnings per share. The company’s revenue was up 5.3% compared to the same quarter last year. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.04%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Insider Activity

In other news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.